US Stem Cell Inc (USRM)

[BearRickPunch]

$USRM
#GoLongFTW

CONVERTIBLE NOTES PAID OFF!!!!!!!

Originally posted by TheHungryHippo 3/15/17
PROOF HERE:

OLD CONVERTIBLE NOTES REMAINING AS OF DEC 31ST, 2016:

The remaining aggregate Magna Group promissory notes unconverted principle balance as of December 31, 2016 was $130,455.

The remaining aggregate promissory notes to Fourth Man unconverted principle balance as of December 31, 2016 were $100,000

The remaining aggregate promissory notes to Daniel unconverted principle balance as of December 31, 2016 was $7,940

TOTAL UNCONVERTED AS OF DECEMBER 31ST 2016: $238,395

NOW: AFTER DECEMBER 31ST 2016:

In January 2017, the Company issued an aggregate of 1,255,623 shares of its common stock in payment of services rendered and 45,531,246 shares of its common stock in settlement of convertible notes and accrued interest of $58,075 and $1,820, respectively.

In February 2017, the Company issued an aggregate of 76,082,378 shares of its common stock in settlement of convertible notes and interest of $95,435 and $23,642, respectively.

In March 2017, the Company issued 3,225,807 shares of its common stock in payment of $25,000 of legal services and an aggregate of 42,657,254 of its common stock in settlement of convertible notes and interest of $59,865 and $3,571, respectively.

THE TOTAL DOLLAR AMOUNT CONVERTED
UP TO THIS VERY DAY OF MARCH 15TH IN 2017

= $242,408 DOLLARS

CONVERTIBLE NOTES GONEEEEEEEE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

$USRM CASH POSITIVE FOR THE FIRST TIME IN COMPANY HISTORY!

AND NOTES PAID OFF!!!!!

Financial highlights from 2016 include:

_______________________________________________________________________
Sunrise, FL – March 15, 2017 – U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, is pleased to announce the following results from operations for the year ending December 31, 2016.

- Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016

- Current liabilities down by $1.9M or 23.8% from $8.0M in 2015 to
$6.1M in 2016

- Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016

- Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016

- And for the first time in the company’s history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in
2015